BAYN Bayer AG

By Neetha Mahadevan

FRANKFURT--Germany's Bayer AG (BAYRY) said Thursday that its eye treatment EYLEA received approval from the European Commission for the treatment of retinal vein occlusion.

The drug has already been approved in many countries for age-related macular degeneration, or wet AMD, and to treat impaired vision due to macular edema secondary to central retinal vein occlusion, or CRVO.

Bayer HealthCare and Regeneron Pharmaceuticals Inc. (REGN) cooperate on the global development of EYLEA, one of Bayer's blockbuster drugs. Regeneron maintains exclusive rights to EYLEA in the U.S., while Bayer HealthCare has exclusive marketing license rights elsewhere. The companies equally share in the profits from sales of EYLEA, except in Japan, where Regeneron receives a percentage of net sales.

Write to Neetha Mahadevan at neetha.mahadevan@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires